Your donation will support the student journalists of School for Advanced Studies-Wolfson. Your contribution will allow us to purchase equipment and cover our annual website hosting costs.
Incoming Medical Breakthroughs
December 18, 2022
In the U.S. 10.5% of the population, or 34.2 million people of all ages, had diabetes. When you have diabetes, your body either produces insufficient insulin or uses it improperly. Too much blood sugar remains in your bloodstream when there is insufficient insulin or when cells cease reacting to insulin. That may eventually result in major health issues like heart disease, eye loss, and renal disease. Coping with diabetes can be overwhelming. For example, you must regularly check your blood sugar levels, choose healthy foods, engage in physical activity, remember to take your medication, and make other wise health decisions. Along with being concerned about your blood sugar levels, whether they are low or high, how much your medications will cost, and whether you will experience diabetes-related consequences like heart disease or nerve damage.
“Trying to manage diabetes is hard because if you don’t, there are consequences you’ll have to deal with later in life.”
Bryan Adams, Canadian singer
Medical researchers have been working to develop better treatments and healthy habits due to
the large number of individuals suffering across the nation. Since introducing the first commercial insulin in the world in 1923, Eli Lilly and Company’s or Lilly has been a leader in the treatment of diabetes worldwide. They continue to advance in developing new therapeutics for individuals who have diabetes by attempting to accommodate the various requirements of those with the disease and those who provide care for them. In order to improve glycemic control in adults with type 2 diabetes, the U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company’s (NYSE: LLY) new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist MounjaroTM (tirzepatide) injection. Patients with type 1 diabetes are not advised to take Mounjaro since it has not been researched in those with a history of pancreatitis.